Phase I/II Ovarian + Chemotherapy

Authors: Alvarez Secord A, Jones EL, Hahn CA, Petros WP, Yu D, Havrilesky LJ, Soper JT, Berchuck A, Spasojevic I, Clarke-Pearson DL, Prosnitz LR, Dewhirst MW.
Publication: Int J Hyperthermia. 2005 Jun;21(4):333-47.

OBJECTIVE:
A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined with hyperthermia has been shown to increase both liposomal delivery and drug extravasation into tumour xenografts resulting in enhanced cytotoxic effects.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: M Romano, S Maluta, C Cordiano, G.G Delaini, M Genna, C Oliani, P Capelli, A Tomezzolli, C Manfrini, A.B Porcaro, M Gabbani, G Chierego
Publication: International Journal of Radiation Oncology, October 1, 2003Volume 57, Issue 2, Supplement, Pages S386–S387

PURPOSE:
To evaluate toxicity and pathological complete response rate in treating preoperatively rectal cancer patients by radiation dose escalation combined with RH + CT.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Rau B, Wust P, Hohenberger P, Löffel J, Hünerbein M, Below C, Gellermann J, Speidel A, Vogl T, Riess H, Felix R, Schlag PM.
Publication: Ann Surg. 1998 Mar;227(3):380-9. Review.

OBJECTIVE:
A prospective phase II study was performed to determine the feasibility and efficacy in terms of response rate, resectability, and morbidity in patients with locally advanced rectal cancer who received preoperative regional hyperthermia combined with radiochemotherapy (HRCT).

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Rau B, Wust P, Tilly W, Gellermann J, Harder C, Riess H, Budach V, Felix R, Schlag PM.
Publication: Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):381-91.

PURPOSE:
Preoperative radiochemotherapy (RCT) is a widely used means of treatment for patients suffering from primary, locally advanced, or recurrent rectal cancer. We evaluated the efficacy of treatment due to additional application of regional hyperthermia (HRCT) to this conventional therapy regime in a Phase II study, employing the annular phased-array system BSD-2000 (SIGMA-60 applicator). The clinical results of the trial were encouraging. We investigated the relationship between a variety of thermal and clinical parameters in order to assess the adequacy of thermometry, the effectiveness of hyperthermia therapy, and its potential contribution to clinical endpoints.

Phase II Bladder + Radiotherapy + Chemotherapy

Authors: Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, Sauer R, Ott OJ.
Publication: Radiother Oncol. 2009 Nov;93(2):358-63. doi: 10.1016/j.radonc.2009.09.018.

PURPOSE:
To assess the safety and effectiveness of treating high-risk T1 and T2 bladder cancer with transurethral resection (TUR-BT) followed by radiochemotherapy (RCT) combined with regional deep hyperthermia (RHT).

Phase II Cervical + Radiotherapy + Chemotherapy

Authors: Sreenivasa G, Hildebrandt B, Kümmel S, Jungnickel K, Cho CH, Tilly W, Böhmer D, Budach V, Felix R, Wust P.
Publication: Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1159-67. Epub 2006 Sep 18.

PURPOSE:
To evaluate preoperative radiochemotherapy combined with regional pelvic hyperthermia in patients with nonresectable cervical cancer >/= International Federation of Gynecology and Obstetrics (FIGO) IIB "bulky" in a Phase II study.

Phase II Rectal + Radiohemotherapy

Authors: Milani V, Pazos M, Issels RD, Buecklein V, Rahman S, Tschoep K, Schaffer P, Wilkowski R, Duehmke E, Schaffer M.
Publication: Strahlenther Onkol. 2008 Mar;184(3):163-8. doi: 10.1007/s00066-008-1731-8.

PURPOSE:
Encouraging results of phase II studies combining chemotherapy with radiotherapy have been published. In this study, the results of a multimodal salvage therapy including radiochemotherapy (RCT) and regional hyperthermia (RHT) in preirradiated patients with recurrent rectal cancer are reported.

Phase III Cervical + Radiotherapy + Brachytherapy

Authors: Franckena M, Lutgens LC, Koper PC, Kleynen CE, van der Steen-Banasik EM, Jobsen JJ, Leer JW, Creutzberg CL, Dielwart MF, van Norden Y, Canters RA, van Rhoon GC, van der Zee J.
Publication: Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):242-50. doi: 10.1016/j.ijrobp.2008.03.072. Epub 2008 Nov 5.

PURPOSE:
To report response rate, pelvic tumor control, survival, and late toxicity after treatment with combined radiotherapy and hyperthermia (RHT) for patients with locally advanced cervical carcinoma (LACC) and compare the results with other published series.

Phase I/II Prostate + Radiotherapy

Authors: Kalapurakal JA, Mittal BB, Sathiaseelan V.
Publication: Br J Radiol. 2001 Aug;74(884):745-51.

PURPOSE:
The purpose of this report is to present the preliminary results of re-irradiation and external hyperthermia in patients with locally advanced, previously irradiated, hormone refractory prostate cancer.

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Maluta S, Romano M, Dall'oglio S, Genna M, Oliani C, Pioli F, Gabbani M, Marciai N, Palazzi M.
Publication: Int J Hyperthermia. 2010;26(2):108-17. doi: 10.3109/02656730903333958.

PURPOSE:
To evaluate the safety of delivering pre-operative regional hyperthermia (HT) plus an intensified chemo-radiotherapy (CRT) regimen in patients suffering from locally advanced rectal cancer.

Open Label Pancreatic + Radiotherapy + Chemotherapy

Authors: Maluta S, Schaffer M, Pioli F, Dall'oglio S, Pasetto S, Schaffer PM, Weber B, Giri MG.
Publication: Strahlenther Onkol. 2011 Oct;187(10):619-25. doi: 10.1007/s00066-011-2226-6. Epub 2011 Sep 19.

PURPOSE:
To evaluate the therapeutic effect of delivering regional hyperthermia (HT) plus chemoradiotherapy (CRT) in patients suffering from locally advanced unresectable pancreatic cancer (LAPC).

Phase I/II Prostate + Radiotherapy

Authors: Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, Felix R, Wust P.
Publication: Strahlenther Onkol. 2005 Jan;181(1):35-41.

PURPOSE:
Since long-term results of the standard treatment of locally advanced or recurrent prostatic carcinoma are unsatisfactory, the role for additional regional hyperthermia was evaluated in a phase I/II study.

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, Hiddemann W, Issels RD.
Publication:J Clin Oncol. 2002 Jul 15;20(14):3156-64.

PURPOSE:
From 1991 to 1997, 58 patients with HR-STS at RP/V sites were prospectively treated with four cycles of etoposide, ifosfamide, and doxorubicin combined with RHT followed by surgery, adjuvant chemotherapy, and radiation.

Phase I/II Prostate + Radiotherapy

Authors: Kaplan I, Kapp DS, Bagshaw MA.
Publication: Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):551-4.

ABSTRACT:
At Stanford, six patients underwent a course of external radiotherapy after local recurrence following 125-iodine implantation.

Phase II Deep Tumor + Radiotherapy + Chemotherapy

Authors: Tilly W, Wust P, Rau B, Harder C, Gellermann J, Schlag P, Budach V, Felix R.
Publication: Int J Hyperthermia. 2001 Mar-Apr;17(2):172-88.

PURPOSE:
The system BSD 2000 has been in clinical use for regional hyperthermia for more than 10 years. Several technical details of this hyperthermia system, as well as the results of clinical studies employing this system have been investigated. The intention of this paper is to investigate the correlation between technical efficiency or feasibility of hyperthermia with the BSD 2000, in terms of power densities and temperatures depending upon parameters such as tumour histology, tumour location, patient age, patient sex, and patient cross section.

Phase III Cervical + Radiotherapy

Authors: van der Zee J, González GD.
Publication: Int J Hyperthermia. 2002 Jan-Feb;18(1):1-12.

BACKGROUND:
Radiotherapy plus hyperthermia was compared to radiotherapy alone in the Dutch Deep Hyperthermia Trial, in patients with advanced bladder, cervical, and rectal tumours. The overall results, published elsewhere, demonstrate that addition of hyperthermia to radiotherapy improves both pelvic control and overall survival rates. The therapeutic gain appeared especially worthwhile in locally advanced cervical tumours. Here, the results in patients with cervical cancer are summarized and discussed, and further details provided.

Phase I/II Soft Tissue Sarcoma + Radiotherapy

Authors: Prosnitz LR, Maguire P, Anderson JM, Scully SP, Harrelson JM, Jones EL, Dewhirst M, Samulski TV, Powers BE, Rosner GL, Dodge RK, Layfield L, Clough R, Brizel DM.
Publication: Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):941-9.

PURPOSE:
To explore the use of a novel program of preoperative radiation and hyperthermia in the management of high-grade soft tissue sarcomas (STS).

Phase II Soft Tissue Sarcoma + Radiotherapy + Chemotherapy

Authors: Schlemmer M, Wendtner CM, Lindner L, Abdel-Rahman S, Hiddemann W, Issels RD.
Publication: Int J Hyperthermia. 2010;26(2):127-35. doi: 10.3109/02656730903335995.

PURPOSE:

We report data from phase II trials examining the efficacy of multimodality treatment with neoadjuvant chemotherapy, hyperthermia, surgery, radiation and postoperative thermochemotherapy in adult patients with high-risk sarcomas of the extremities.

Pilot Study Pediatric Germ Cell + Radiotherapy + Chemotherapy

Authors: Wessalowski R, Blohm M, Calaminus G, Engert J, Harms D, Krause I, Kruck H, Grüttner HP, Pape H, Göbel U.
Publication: Klin Padiatr. 1997 Jul-Aug;209(4):250-6.

PURPOSE:
In this study treatment results in children and adolescents (n = 32) suffering from loco-regional abdominal relapses of germ cell tumors (GCT) (7 embryonal carcinoma, 17 Yolk sac tumors, 8 immature teratomas) aged from 1;0 to 23;3 years (mean = 10;11 years) were evaluated.